Document Detail

Abnormal levels of circulating endothelial progenitor cells during exacerbations of COPD.
MedLine Citation:
PMID:  20082199     Owner:  NLM     Status:  MEDLINE    
Cardiovascular morbidity and mortality is increased in patients with chronic obstructive pulmonary disease (COPD). Reduced levels of circulating endothelial progenitor cells (EPCs) are associated with increased risk of death in patients with stable coronary artery disease (CAD). Likewise, during acute events of CAD, the number of circulating EPCs increases under the influence of vascular endothelial growth factor (VEGF) and systemic inflammation. Abnormal levels of circulating EPCs have been reported in patients with COPD. However, the response of EPCs to episodes of exacerbation of the disease (ECOPD) has not been investigated yet. We hypothesized that similar to what occurs during acute events of CAD, levels of circulating EPCs would increase during ECOPD. We compared levels of circulating EPCs (assessed by the % of CD34(+)KDR(+) cells determined by flow cytometry) in patients hospitalized because of ECOPD (n = 35; 65 +/- 9 years [mean +/- SD]; FEV(1) = 46 +/- 15% predicted), patients with stable COPD (n = 44; 68 +/- 8 years; FEV(1) = 49 +/- 17% predicted), smokers with normal lung function (n = 10; 60 +/- 9 years), and healthy never smokers (n = 10; 62 +/- 4 years). To investigate potential mechanisms of EPC regulation, we assessed both VEGF and high-sensitivity C-reactive protein (hsC-RP) in plasma. Our results show that EPC levels were higher (p < 0.05) in patients with ECOPD (1.46 +/- 1.63%) than in those with stable disease (0.68 +/- 0.83%), healthy smokers (0.65 +/- 1.11%), and healthy never smokers (1.05 +/- 1.36%). The percentage of circulating EPCs was positively related to VEGF plasma levels during ECOPD (r = 0.51, p = 0.003). In a subset of 12 patients who could be studied during both ECOPD and clinical stability, the EPCs levels increased during ECOPD. We conclude that EPC levels are increased during ECOPD, likely in relation to VEGF upregulation.
Ernest Sala; Cristina Villena; Catalina Balaguer; Angel Ríos; Carlos Fernández-Palomeque; Borja G Cosío; Javier García; Aina Noguera; Alvar Agustí
Related Documents :
10377199 - Increased exhaled nitric oxide in patients with stable chronic obstructive pulmonary di...
7744199 - Does phase 2 of the expiratory pco2 versus volume curve have diagnostic value in emphys...
2766809 - Bronchial foreign body vs asthma.
21054669 - Laryngeal penetration and aspiration in individuals with stable copd.
19404699 - Prevalence and clinical feature of the "overlap syndrome", obstructive sleep apnea (osa...
16889949 - The cost of treating patients with copd in denmark--a population study of copd patients...
22456769 - Nt-probnp levels at spontaneous breathing trial help in the prediction of post-extubati...
6652009 - Gastric emptying following premedication with glycopyrrolate or atropine.
11953279 - Influence of mucolytic therapy on respiratory mechanics in patients with chronic obstru...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-01-14
Journal Detail:
Title:  Lung     Volume:  188     ISSN:  1432-1750     ISO Abbreviation:  Lung     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-08     Completed Date:  2010-10-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7701875     Medline TA:  Lung     Country:  United States    
Other Details:
Languages:  eng     Pagination:  331-8     Citation Subset:  IM    
Servei de Pneumologia, Hospital Universitari Son Dureta, 07014, Palma de Mallorca, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, CD34 / blood
C-Reactive Protein / analysis
Disease Progression
Endothelial Cells / pathology*
Middle Aged
Prospective Studies
Pulmonary Disease, Chronic Obstructive / blood*,  pathology*
Smoking / adverse effects,  epidemiology
Stem Cells / pathology*
Vascular Endothelial Growth Factor A / blood
Reg. No./Substance:
0/Antigens, CD34; 0/Vascular Endothelial Growth Factor A; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Corticosteroids and Montelukast: Effects on Airway Epithelial and Human Umbilical Vein Endothelial C...
Next Document:  Comparison of orbital floor triamcinolone acetonide and oral prednisolone for cataract surgery manag...